Clinical trial NCT03218683: Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.
Official title: A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML)
Keywords: relapsed
refractory
AZD5991
Acute Myeloid Leukemia (AML)
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2017-07-14
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: This study is a 3 part, multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability,pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 alone or in combination with venetoclax in subjects with relapsed or refractory hematologic malignancies.
Primary purpose: TREATMENT

Brief summary: This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies Part 1 of the study is monotherapy dose escalation. Closed November 2020 Part 2 of the study is monotherapy expansion groups for relapsed/refractory chronic lymphocytic leukaemia (CLL), AML/ myelodysplastic syndromes (MDS), and multiple myeloma (MM). Closed November 2020 Part 3 is a sequential, dose-escalation study of the combination of AZD5991 and venetoclax in subjects with relapsed/refractory AML


Eligibility criteria: Inclusion Criteria (AZD5991 + venetoclax):

* Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling and analyses.
* Men and women 18 to 85 years of age, inclusive.
* Diagnosis of AML and histologically proven based on criteria established by the World Health Organisation (WHO) as documented by medical records. Must have a measurable blast infiltration in bone marrow which will serve as a response parameter
* Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.
* Must have received at least 1 prior line of therapy and there must be no treatment options available known to provide clinical benefit. Refer to National Comprehensive Cancer Network (NCCN) guidelines.
* Documented active disease requiring treatment per respective NCCN guideline that is relapsed or refractory defined as:
* Recurrence of disease after response to prior line(s) of therapy.
* Or progressive disease after completion of the treatment regimen preceding entry into the study.
* WBC ≤10,000 cells/mm3 (10 x 109/L); use of leukapheresis or hydroxyurea before study drug initiation is allowed to achieve this entry criterion.
* Adequate hepatic and renal function at screening defined as:
* Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0 x upper limit of normal (ULN).
* Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
* Serum creatinine ≤1.5 times ULN and creatinine clearance ≥50 mL/min (measured or calculated by Cockcroft and Gault equation \[(140-Age) • Mass (kg)/(72 • creatinine mg/dL) • multiply by 0.85 if female\]).
* Lipase ≤1.5 x ULN and serum amylase ≤1.5 x ULN and no history of pancreatitis.
* Women should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test before start of dosing if of child-bearing potential or must have evidence of nonchildbearing potential.
* Men should be willing to use barrier contraception (ie, condoms) and refrain from sperm donation during and after the conduct of the trial.

Exclusion Criteria (AZD5991 + venetoclax):

* Treatment with any of the following:

  * Any investigational agents from a previous clinical study within 4 half-lives or 14 days, whichever is the greater, of said prior investigational agent(s) with regard to the first dose of study treatment on this protocol. Washout period not required in subjects with aggressive disease who require treatment sooner.
  * Any other chemotherapy, immunotherapy or anticancer agents within 2 weeks of the first dose of study treatment. Washout period not required in subjects with aggressive disease who require treatment sooner.
  * Any hematopoietic growth factors (eg, filgrastim \[granulocyte colony-stimulating factor; G-CSF\], sargramostin \[granulocyte-macrophage colony-stimulating factor; GM-CSF\]) within 7 days of the first dose of study drug or pegylated G-CSF (pegfilgrastim) or darbepoetin within 14 days of the first dose of study drug.
  * Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
* Except for alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment.
* AML with known active central nervous system involvement.
* As judged by the Investigator, any evidence of severe or uncontrolled systemic disease (eg, severe hepatic impairment, interstitial lung disease \[bilateral, diffuse, parenchymal lung disease\]), or current unstable or uncompensated respiratory or cardiac conditions, or uncontrolled hypertension, history of, or active, bleeding diatheses (eg, hemophilia or von Willebrand disease) or uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment), or intravenous anti-infective treatment within 2 weeks before first dose of study drug.
* Malabsorption syndrome or other condition that precludes enteral route of administration.
* Chronic respiratory disease that requires continuous oxygen use.
* Known diagnosis of a hypercoagulable disorder other than malignancy
* Undergone any of the following procedures or experienced any of the following conditions currently or in the preceding 6 months:

  * angina pectoris
  * supraventricular arrhythmias, including atrial fibrillation, which are uncontrolled
  * Myocarditis
  * heart failure NYHA Class I or above
* Experienced any of the following conditions currently or at any previous timepoint

  * Myocardial infarction (MI)
  * coronary artery bypass graft
  * angioplasty
  * vascular stent
  * Heart failure NYHA Class ≥ 2
  * Ventricular arrhythmias requiring continuous therapy
* Any of the following cardiac criteria:

  * Mean resting corrected QT interval (QTcF) ≥ 450 msec applicable to both genders obtained from 3 electrocardiograms (ECGs) (averaged)
  * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG eg, complete left bundle branch block, second to third degree AV block, sinus node dysfunction with clinically significant sinus pause
  * Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age. Concomitant medications known to prolong QTc should be used with caution and cannot be used starting with the first dose of study drug and through the DLT review period.
  * ST-wave depression and T-wave changes (e.g. inversion or flattened) in recent or screening ECG
  * CPK assay reading ≥ ULN at screening
  * Subjects with any troponin assay reading of ≥ULN during screening
  * Left ventricular ejection fraction \[LVEF\] \<55% with echocardiogram (ECHO) or multi-gated acquisition scan (MUGA). Appropriate correction to be used, if a MUGA is performed.
* History of severe allergic or anaphylactic reactions to BH3 mimetics or history of hypersensitivity to active or inactive excipients of AZD5991.
* Received the following within 7 days before initiation of venetoclax:
* Strong or moderate cytochrome P450 3A (CYP3A) inducers
* Strong or moderate CYP3A inhibitors
* Pg-P inhibitors
* Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days before the initiation of venetoclax.

Primary outcomes:
measure: Incidence of Adverse Events
timeFrame: At every treatment and follow up visit until disease progression. Expected to be for up to 12 months
measure: Dose limiting toxicities
timeFrame: Minimum observation period is 28 days per cohort
measure: maximum tolerated dose
timeFrame: Minimum observation period is 28 days for the maximum dose cohort
Secondary outcomes:
measure: Maximum observed plasma concentration of AZD5991 monotherapy and AZD5991+venetoclax
timeFrame: Predose and through 24 hours postdose
measure: Area under the concentration-time curve for plasma concentrations of AZD5991 monotherapy and AZD5991+venetoclax
timeFrame: Predose and through 24 hours postdose
measure: Objective response rate (ORR)
timeFrame: From time of first dose until discontinuation of AZD5991 monotherapy and AZD5991+venetoclax expected to be for up to 12 months
measure: Duration of response (DOR)
timeFrame: From time of first dose until discontinuation of AZD5991 monotherapy and AZD5991+venetoclax expected to be for up to 12 months
measure: Progression-free survival (PFS)
timeFrame: From time of first dose until first observation of progression expected to be for up to 12 months
measure: Complete remission rate (CRR)
timeFrame: From time of first dose until discontinuation of AZD5991 monotherapy and AZD5991+venetoclax expected to be for up to 12 months
Other outcomes:
Locations:
city: Orange
country: United States
facility: Research Site
state: California
city: Aurora
country: United States
facility: Research Site
state: Colorado
city: Atlanta
country: United States
facility: Research Site
state: Georgia
city: Boston
country: United States
facility: Research Site
state: Massachusetts
city: Saint Louis
country: United States
facility: Research Site
state: Missouri
city: New York
country: United States
facility: Research Site
state: New York
city: Columbus
country: United States
facility: Research Site
state: Ohio
city: Portland
country: United States
facility: Research Site
state: Oregon
city: Nashville
country: United States
facility: Research Site
state: Tennessee
city: Houston
country: United States
facility: Research Site
state: Texas
Study officials:
References:
citation: Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018 Dec 17;9(1):5341. doi: 10.1038/s41467-018-07551-w.